# Longitudinal changes in [18F]FDG PET brain metabolism as a prognostic marker in autoimmune encephalitis

## TL;DR

This study shows that brain metabolism changes seen in PET scans can predict long-term outcomes in autoimmune encephalitis patients.

## Contribution

The study identifies specific brain regions whose metabolic changes correlate with clinical outcomes in autoimmune encephalitis.

## Key findings

- Three brain regions showed significant metabolic changes between baseline and follow-up PET scans.
- Poorer metabolic recovery in these regions correlated with greater disability and relapses.
- Lower baseline metabolism in one region predicted higher disease severity and treatment escalation.

## Abstract

Recent advancements in autoimmune encephalitis (AE) have enhanced diagnosis and management, but predicting long-term outcomes remains challenging. This study aims to evaluate longitudinal changes in brain [18F]FDG PET patterns in AE patients to identify specific regional metabolic variations and predict clinical outcomes.

This longitudinal study compared brain [18F]FDG PET scans of 22 AE patients at baseline (BS) and after treatment follow-up (FU) using voxel-wise paired t-tests. Significant clusters with at least 100 voxels and p < 0.05 were identified and designated as volumes of interest (VOIs). The VOI values were correlated with main clinical outcomes using partial Spearman’s tests, and their prognostic significance was assessed through regression models.

Three VOIs showed significant metabolic changes between baseline (BS) and follow-up (FU) assessments. VOI-A, which was relatively hypermetabolic at BS, included the caudate-thalamus-parahippocampal region, right amygdala, and anterior cingulate cortex. VOI-B1 and VOI-B2, relatively hypometabolic at BS, corresponded to the right fusiform gyrus, precuneus, and temporo-parietal cortex, respectively. Poorer metabolic recovery in all VOIs to normalcy correlated with greater disability (mRS) in both acute and post-therapy phases. Lower metabolism in BS VOI-B1 predicted higher Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score at FU and relapses, while lower age was a significant predictor of escalation to second-line treatment.

Longitudinal [18F]FDG PET reveals distinct regional metabolic changes paralleling clinical recovery post-treatment in AE. Temporo-parietal metabolism correlates with relapses, clinical severity, and functional impairment, highlighting [18F]FDG PET as a biological tracker of disease activity throughout AE and its prognostic value.

The online version contains supplementary material available at 10.1007/s00259-025-07526-2.